Brain peptide research may lead to promising new treatments for mental illnesses
A new review looks at where such research stands and what additional studies are necessary. "There is a need for new and better drugs for mental illnesses. An accumulation of recent research points to potential that relaxin-3 and its receptor RXFP3 may be a new target for treatment of these disorders," said Dr. Gavin Dawe, senior author of the British Journal of Pharmacology review. "Developments in stapled peptide technology -- whereby peptides are chemically stabilized by crosslinking with small molecules -- are now opening prospects for selectively targeting RXFP3 to develop a new class of drugs for mental illnesses." for more information visit our product website: Buy Vidalista 60 mg Online